--- title: "New Stock News | Oversubscribed nearly 700 times! Leading puncture surgery robot company TH MEDICAL completes its IPO and will be listed on the Hong Kong Stock Exchange on June 30" type: "News" locale: "en" url: "https://longbridge.com/en/news/290812987.md" description: "The domestic puncture surgery robot leader TH MEDICAL completed its IPO on June 25, with an oversubscription of nearly 700 times (reaching 682.43 times), raising a total of over HKD 32.9 billion. The company is expected to be listed on the Hong Kong Stock Exchange main board on June 30, with an issue price of HKD 119.30-135.40 per share. As a leader in its niche market, its core products have received NMPA certification, holding the top market share" datetime: "2026-06-25T10:15:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/290812987.md) - [en](https://longbridge.com/en/news/290812987.md) - [zh-HK](https://longbridge.com/zh-HK/news/290812987.md) --- # New Stock News | Oversubscribed nearly 700 times! Leading puncture surgery robot company TH MEDICAL completes its IPO and will be listed on the Hong Kong Stock Exchange on June 30 According to the Zhitong Finance APP, the domestic puncture mobile ablation surgical robot leader, TH MEDICAL-B (02697), has officially closed its subscription on June 25, with market funds showing strong enthusiasm, achieving impressive performance in the segmented track. According to statistics compiled by Futu Securities, the public offering of TH MEDICAL corresponds to a fundraising scale of approximately HKD 48.27 million, with the total amount of financing subscriptions in the market reaching as high as HKD 32.941 billion, and the financing subscription multiple reaching 682.43 times, indicating significant fund enthusiasm. Nearly 20 brokerages participated in the financing subscription, with Futu Securities leading the way with a financing subscription amount of HKD 22.951 billion; Tiger Brokers and Huatai International followed closely, with financing subscription scales of HKD 4.107 billion and HKD 1.713 billion, respectively; Phillip Securities and ZhiFu Securities also exceeded HKD 1 billion and HKD 815 million in subscription amounts, reflecting a diverse range of funds optimistic about TH MEDICAL's long-term growth potential. TH MEDICAL's issuance pricing range is between HKD 119.30 and HKD 135.40 per share, with a trading unit of 20 shares, making the entry threshold approximately HKD 2,735.30. The first stock of puncture surgical robots is expected to officially land on the main board of the Hong Kong Stock Exchange on June 30, with China International Capital Corporation and DBS Asia Capital serving as joint sponsors for this listing. Established in 2018 and headquartered in the Hengqin Guangdong-Macao Deep Cooperation Zone, TH MEDICAL has been deeply engaged in the puncture surgical robot track for eight years, focusing on the self-research and commercialization of the entire chain of percutaneous puncture and ablation surgical robots, building a complete matrix of minimally invasive tumor diagnosis and treatment products. The core products of the percutaneous puncture surgical robot include four mature models: TH-S1, TH-S, TH-S Pro, and TH-SA, all of which have obtained NMPA Class III medical device registration certificates, covering the clinical demand for precise puncture of lung and abdominal organs. Data from third-party consulting firm ZhiShi confirms its leading position: by 2025, in the domestic percutaneous puncture surgical robot track, the company's shipment market share is expected to be 36.4%, and revenue market share is expected to be 28.0%, both ranking first in the industry. In terms of pipeline layout, TH MEDICAL is simultaneously building a product lineup for ablation surgical robots, organ preservation, and other tracks. The key product, the ablation surgical robot TH-X MW, has been recognized by the National Medical Products Administration as "internationally innovative," and has simultaneously secured two treatment indications for liver and lung tumors; the iterative model TH-X HMW has been approved for liver tumor ablation; at the same time, it has reserved compact puncture surgical robots TH-P series, MW150 microwave equipment, cryoablation robot TH-X Cryo, as well as internationally advanced and domestically scarce in vitro organ room temperature preservation evaluation equipment, forming a dual growth curve of short-term commercialization and long-term cutting-edge innovation. Market analysts point out that against the backdrop of domestic substitution of high-end medical equipment and the continuous expansion of demand for minimally invasive tumor treatment, TH MEDICAL holds dual core technology certifications of domestic and international innovation, coupled with the commercial achievements of being the first in the puncture track, highlighting its scarce hard technology attributes. The massive oversubscription during this IPO phase fully reflects investors' high recognition of the track space and the company's growth certainty, and its dark market trend and performance on the first day of listing may become a core sentiment barometer for the Hong Kong stock medical device and surgical robot sub-sector ### Related Stocks - [02697.HK](https://longbridge.com/en/quote/02697.HK.md) - [FUTU.US](https://longbridge.com/en/quote/FUTU.US.md) - [03588.HK](https://longbridge.com/en/quote/03588.HK.md) - [TIGR.US](https://longbridge.com/en/quote/TIGR.US.md) - [06886.HK](https://longbridge.com/en/quote/06886.HK.md) - [601688.CN](https://longbridge.com/en/quote/601688.CN.md) - [00388.HK](https://longbridge.com/en/quote/00388.HK.md) - [03908.HK](https://longbridge.com/en/quote/03908.HK.md) - [601995.CN](https://longbridge.com/en/quote/601995.CN.md) - [D05.SG](https://longbridge.com/en/quote/D05.SG.md) - [HTSC.UK](https://longbridge.com/en/quote/HTSC.UK.md) - [80388.HK](https://longbridge.com/en/quote/80388.HK.md) - [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md) ## Related News & Research - [ZhenHealth's HK IPO tests global appetite for pre-revenue medical assets](https://longbridge.com/en/news/290939539.md) - [MicroPort MedBot’s Toumai Surgical Robot Tops 200 Global Installations](https://longbridge.com/en/news/290990958.md) - [Duly Becomes First Ambulatory Surgery Center in Illinois to Offer Da Vinci 5 Surgical Robot](https://longbridge.com/en/news/290857008.md) - [Johnson & Johnson launches Dual Energy THERMOCOOL SMARTTOUCH SF cardiac ablation platform in Europe](https://longbridge.com/en/news/290802892.md) - [From Telegram Bot to the Full-Fledged Platform: 001k.bot Launches Web Dashboard](https://longbridge.com/en/news/290982136.md)